Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH607 in Major Depressive Disorder
NCT07741331Phase 3Not yet recruiting
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 3 trial of KH607 in major depressive disorder (MDD), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
KH607
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07741331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07741331.